Home › Funds › Tri Locum Partners LP › TARS
Tri Locum Partners LP position in TARS
TARSUS PHARMACEUTICALS INC · Health Care
Tri Locum Partners LP reported holding 328,340 shares of TARS (TARSUS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$20.7M, representing 2.54% of its reported portfolio and ranking #14 among its reported holdings. Tri Locum Partners LP has disclosed TARS holdings in 4 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Tri Locum Partners LP's TARS position evolved
Tri Locum Partners LP first disclosed a stake in TARS in Q2 2025 at 177,656 shares (US$7.2M). The position peaked in Q2 2026 at 328,340 shares, worth US$20.7M. Across 4 filings, Tri Locum Partners LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 328,340 shares valued at US$20.7M — an increase of 75,752 shares quarter over quarter.. Notable position changes include a 33% trim in Q3 2025 (shares rose 38% over the following quarter), a 30% increase in Q2 2026 (shares rose 25% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 177.66K | $7.20M | New |
| Q3 2025 | 119.26K | $7.09M | Reduce |
| Q1 2026 | 252.59K | $17.72M | New |
| Q2 2026 | 328.34K | $20.67M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TARS and 13F data
TARS (TARSUS PHARMACEUTICALS INC) is a Health Care company. 39 other funds we track also report a position in TARS — the largest reported positions include Deep Track Capital, LP (US$230.8M), RTW INVESTMENTS, LP (US$211.3M), Paradigm Biocapital Advisors LP (US$174.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TARS
- Deep Track Capital, LP 3.67M sh · $230.79M · Q2 2026
- RTW INVESTMENTS, LP 3.36M sh · $211.29M · Q2 2026
- Paradigm Biocapital Advisors LP 2.78M sh · $174.70M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.57M sh · $98.71M · Q2 2026
- Vestal Point Capital, LP 1.05M sh · $66.09M · Q2 2026
- Frazier Life Sciences Management, L.P. 728.64K sh · $45.86M · Q2 2026
- MPM BioImpact LLC 322.01K sh · $20.27M · Q2 2026
More on Tri Locum Partners LP
FAQ
How long has Tri Locum Partners LP held TARS?
Tri Locum Partners LP has disclosed TARS holdings in 4 of the last 5 reported quarters, going back to Q2 2025.
What is Tri Locum Partners LP's current position in TARS?
As of Q2 2026, Tri Locum Partners LP holds 328.34K shares of TARS (TARSUS PHARMACEUTICALS INC), valued at $20.67M, representing 2.54% of its reported portfolio and ranking #14.
Has Tri Locum Partners LP been buying or selling TARS?
In the latest 13F filing (Q2 2026), Tri Locum Partners LP increased its position in TARS. The position peaked in Q2 2026 at 328.34K shares.
Which other funds hold TARS?
Other major institutional holders of TARS include Deep Track Capital, LP, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.